New drug for advanced lung cancer with a specific EGFR mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment for advanced non-small cell lung cancer that has a specific change in the EGFR gene called 19delins. It is for people who have not had any previous treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- A test on your tumor or blood shows you have an EGFR 19delins mutation.
- You have not had any other cancer treatment for advanced disease.
- You are able to take pills by mouth.
- You are in generally good health (able to do daily activities) and have a life expectancy of at least 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests adding icotinib (an EGFR-targeted pill) to chemotherapy before surgery for people with certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or better control the cancer before it’s removed with an operation.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
This trial tests different treatments after surgery for people with non-squamous lung cancer that has certain high-risk features. The goal is to find the best next step to lower the chance of the cancer coming back, based on the type of gene change in the tumor.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.